



DR. KNS MEMORIAL

INSTITUTE OF MEDICAL SCIENCES

(Formerly known as Mayo Institute of Medical Sciences)

(A Unit of Bodhisatva Charitable Trust)

Ref. No.: KNSMIMS/EX-Cell./2025/141

DATES: 04.09.2025

DEPARTMENT OF MEDICAL EDUCATION

TIME TABLE

For

PHASE 2 MBBS STUDENTS OF 2024 BATCH

AS PER

NMC COMPETENCY BASED CURRICULUM

(CBME 2024)

COLOR CODES

PATHOLOGY **MICROBIOLOGY** **PHARMACOLGY**

FMT **COMM. MED.** **MEDICINE** **SURGERY** **OBG**

CLINICAL POSTINGS & Certified Procedural Skills in Skill Lab.
(ALSO IN SEPARATE TIME TABLE)

AETCOM

PANDEMIC MODULE

INTEGRATION

VERTICAL INTEGRATION
VI

HORIZONTAL INTEGRATION
HI

Integrated Topics



Aligned Topics



HOLIDAY / EXAMS



SPORTS & EXTRA CURRICULAR ACTIVITY



**DISTRIBUTION OF TEACHING HOURS FOR ALL THE SUBJECTS IN PHASE
-2 (AS PER NMC) MBBS BATCH 2023-24
FOR THE ACADEMIC YEAR 2024-25 W.E.F 26.10.2024**

SUBJECT	LECTURES	SMALL GROUP TEACHING (TUTORIAL / INTEGRATED LEARNING / PRTACTICALS)	Clinical Postings (hours*)	SDL	TOTAL
PATHOLOGY	80	165		10	255
PHARMACOLOGY	80	170		10	260
MICROBIOLOGY	70	135		10	215
COMMUNITY MEDICINE	15	0		10	25
FAMILY ADOPTION PROGRAMME	0	0	30		30
FORENSIC MEDICINE & TOXICOLOGY	12	22		8	42
CLINICAL SUBJECTS	59		540		599
AETCOM MODULE		29		8	37
PANDEMIC MODULE				28	28
SPORTS & EXTRACURRICULAR ACTIVITIES				35	35
TOTAL	316	516	585	104	1521

MBBS-2024 BATCH PHASE-2 TEACHING SCHEDULE

W.E.F. – After declaration of Phase 1 results

Date & Day	8 to 9 AM	9 to 10 AM	10 AM to 1 PM CLINICAL POSTING	2 to 4 PM
After declaration of Phase 1 results	Patho (Orientation/lec) PA 1.1/1.2 Describe the role of a pathologist in diagnosis and management of disease	Micro (Lec) MI 1.1 Intro & history of Microbiology		Micro - Batch A (SGD) MI 1.1 Microscopy
	Pharma (Lec-1) PH 1.1 Introduction & Principles of Pharma	Patho (Lec) PA 1.3 Describe the history and evolution of Pathology		Pharma - Batch B (Practical-1) PH 1.3 Introduction & Drug Nomenclature
	Medicine (Lec.) GM 4.1 Febrile Response VI(MI)	Pharma (Lec-2) PH 1.2 & PH 10.12 Evidence based medicine & Drug development		Micro - Batch B (SGD) MI 1.1 Microscopy
	Micro (Lec) MI 1.2 Bacterial taxonomy and Morphology	Patho (Lec) PA 2.1 Demonstrate knowledge of the causes, mechanisms, types and effects of cell injury and their		Pharma - Batch A (Practical-2) PH 1.3 Introduction & Drug Nomenclature
				Path - Batch A (DOAP) PA 2.8 Orientation/Identify and describe various forms of cell injuries, their manifestations and ...
				Comm. Med. - Batch B (SGD) CM 3.1 Health hazards of air, water, noise, radiation and pollution Hi(EN) VI(IM)
				Path - Batch B (DOAP) PA 2.8 Orientation/Identify and describe various forms of cell injuries, their manifestations and consequences in gross
				Comm. Med. - Batch A (SGD)

		clinical significance		CM 3.1 Health hazards of air, water, noise, radiation and pollution Hi(EN) VI(IM)
	Obs. & Gyn. (Lec.) OG 2.1 Development & anatomy of the female reproductive tract, VI(AN)	Micro (Lec) MI 1.2 Bacterial Physiology		Patho (SGD) PA 2.2 Distinguish between reversible-irreversible injury: mechanisms; morphology of cell injury
	Comm. Med. (Lec.) CM 7.1 Epidemiology VI(IM)	Pharma (Lec-3) PH 1.5 Route of Drugs Administration		Pharma (SGD-1) PH 1.4 Drug delivery & Drug Formulation
	Patho (Lec) PA 2.3 Intracellular accumulation of fats, proteins, carbohydrates, pigments	Micro (Lec) MI 1.12 Sterilization VI(SU)		AETCOM (CM) Module 2.1: The foundations of communication – 2 Introduction
	Pharma (Lec-4) PH 1.6 Pharmacokinetics -1	Patho (SGD) PA 2.4 Describe and discuss Cell death- types, mechanisms, necrosis, apoptosis (basic as contrasted with necrosis), autolysis		Micro - Batch A (SGD) (MI 1.5 Sterilization & Disinfection)
	Surgery (Lec) SU 14.1 Aseptic Techniques / Sterilization & Disinfection VI(MI)	Pharma (Lec-5) PH 1.6 Pharmacokinetics -2		Pharma - Batch B (Practical-3) PH 10.4 & 10.5 Basic of Prescription writing, Legal aspect
				Micro- Batch B (SGD) (MI 1.5 Sterilization & Disinfection)
				Pharma - Batch A (Practical-5) PH 10.4 & 10.5 Basic of Prescription writing, Legal aspect
				Path - Batch A (DOAP) PA 3.2 - Identify and describe amyloidosis in a pathology specimen
				Comm. Med - Batch B (SGD) CM 3.2 Water - Uses & Sources

	<p>Micro (Lec) MI 1.12,1.13 Disinfection VI(SU)</p>	<p>Patho (SGD) PA 2.5 Describe and discuss pathologic calcifications, gangrene</p>		<p>Path - Batch - B (DOAP) PA 3.2 - Identify and describe amyloidosis in a pathology specimen</p>	
	<p>Obs. & Gyn. (Lec.) OG 3.1 Physiology of Female Reprod. System VI(PY)</p>	<p>Micro (SDL) MI 1.12,1.13 (Ster. & Dis.) VI(SU)</p>		<p>Comm. Med - Batch A (SGD) CM 3.2 Water - Uses & Sources</p>	
	<p>Comm. Med. (Lec.) CM 7.2 Modes of Transmission of Infectious Dis. VI(IM)</p>	<p>Pharma (Lec-7) PH 1.7 & 1.9 Pharmacodynamics -1</p>		<p>2-3 PM Patho (SGD) PA 2.6 Describe and discuss cellular adaptations: atrophy, hypertrophy, hyperplasia, metaplasia, dysplasia</p>	<p>3-4 PM Pharma (Lec-6) PH 1.6 Pharmacokinetics-3</p>
	<p>Patho (Lec) PA 2.7 Describe and discuss the mechanisms of cellular aging and apoptosis</p>	<p>Micro (Lec) MI 1.4</p>		<p>AETCOM (CM) Module 2.1: The foundations of communication – 2 (Focused small group session)</p>	
	<p>Pharma(Lec-8) PH 1.7 &1.9 Pharmacodynamics -2</p>	<p>Patho (Lec) PA 3.1 Describe the pathogenesis and pathology of amyloidosis</p>		<p>Micro - Batch A (SGD) (MI 1.1 Gram staining)</p>	<p>Pharma - Batch B (Practical-6) PH 1.5 Solid/oral Dosage Forms-1</p>
				<p>Micro- Batch B (SGD) (MI 1.1 Gram staining)</p>	<p>Pharma - Batch A (Practical-7) PH 1.5 Solid/ oral Dosage Forms-1</p>

	<p>Medicine (Lec) GM 4.3 Common Bacterial Causes of Fever VI(MI)</p>	<p>Pharma (SGD-2) PH 1.7 ,1.9 & 1.10 Pharmacodynamics -3</p>		<p>Path - Batch A (DOAP) PA 4.4 Identify and describe acute and chronic inflammation in gross and microscopic</p>
	<p>Micro (Lec) MI 1.4 Laboratory methods for detection of infectious agents -II</p>	<p>Patho (Lec) PA 4.1 Define and describe the general features of acute and chronic inflammation including stimuli, ...</p>		<p>Comm. Med - Batch B (SGD) CM 3.3 Water Purification</p>
	<p>Obs. & Gyn. (Lec.) OG 1.1/2 Birth rate, maternal mortality and morbidity VI(CM)</p>	<p>Micro (Lec) MI 1.4 Laboratory methods for detection of infectious agents - III</p>		<p>Path - Batch B (DOAP) PA 4.4 Identify and describe acute and chronic inflammation in gross and microscopic</p>
	<p>Com. Med.(Lec.) CM 7.3 Epidemiological Data VI(IM)</p>	<p>Pharma(Lec-9) PH 1.11 Adverse drug reactions</p>		<p>Comm. Med - Batch A (SGD) CM 3.3 Water Purification</p>
	<p>Patho (Lec) PA 4.3 Define and describe chronic inflammation including causes, types non- specific and granulomatous; and enumerate...</p>	<p>Micro (Lec) MI 1.3 Molecular Genetics and molecular techniques</p>		<p>2-3 PM Patho (SGD) PA 4.2 Enumerate and describe the mediators of acute inflammation</p>
				<p>3 - 4 PM Pharma (integrated Seminar- 1) Receptors</p>
				<p>AETCOM (CM) Module 2.1: The foundations of communication – 2 Skill lab Session & Discussion & Closure</p>
				<p>Micro - Batch A (SGD) (MI 1.2 Culture Media)</p>
				<p>Pharma - Batch B (Practica-9) PH 1.5 & 1.6</p>

				Liquid /oral Dosage Forms-2
	Pharma (Lec-10) PH 1.12 PH 10.11 Pharmacovigilance & legal Aspect of drugs	Patho (Lec) PA 5.1 Define and describe the process of repair and regeneration including wound healing and its types		Micro- Batch B (SGD) (MI 1.2 Culture Media)
	Surgery (Lec.) SU6.2 Prophylactic and therapeutic antibiotics	Pharma (Tutorial-1) PH 1.13 Management of Drug Interactions		Pharma - Batch A (Practical-10) PH 1.5 & 1.6 Liquid /oral Dosage Forms-2
	Micro (Lec) MI 11.1 Antimicrobials & AST with interpretation of reports HI(PH)	Patho (SGD) PA 6.1 Define and describe edema, its types, pathogenesis and clinical correlations		Path - Batch A (DOAP)Identify and describe the gross and microscopic features of infarction in a pathologic specimenPA 6.7
	Obs. & Gyn. (Lec.) OG 4.1 Embryology of Fetus Fetal growth, Placenta & Teratogenesis VI(AN)	Micro (SGD) MI 11.1 Genetic basis of drug resistance		Comm. Med - Batch B (SGD) CM 3.2 Small scale Water Disinfection
				Path - Batch B (DOAP)Identify and describe the gross and microscopic features of infarction in a pathologic specimen PA 6.7
				Comm. Med - Batch A (SGD) CM 3.2 Small scale Water Disinfection
				2 - 3 PM Patho (SGD) PA 6.2 Define and describe hyperemia, congestion, hemorrhage
				3 - 4 PM Pharma (Lec-11) PH 2.2 Cholinergic drugs-1

	Com. Med. (Lec.) CM 7.4 Morbidity & Mortality Indicators VI(IM)	Pharma (Lec-12) PH 2.2 Cholinergic drugs-2		PM 2.1 (MI) Infection control- Part II Airborne precautions, contact precautions, ICC
	Pharma (Lec-13) PH 2.2 Anti Cholinergic drugs-1	Patho (Lec) PA 6.3 Define and describe shock, its pathogenesis and its stages		Micro - Batch B (SGD) (MI 1.1/2 Identification of bacteria)
	Medicine (Lec) GM 4.6 Acute Febrile Illness.	Pharma (Lec-14) PH 2.2 Anti Cholinergic drugs-2		Pharma - Batch A (Practical-11) PH 1.5 & 1.6 Inhalational Dosage Forms & device-3
	Mi (1.2 Intro to virology	Patho (SGD) PA 6.4 Define and describe normal haemostasis and the etiopathogenesis and consequences of thrombosis		Path - Batch A (DOAP)Observe a diagnostic cytology and its staining and interpret the specimen PA 8.3
	Comm. Med.(Lec.) CM 7.5 Epidemiological study designs VI(IM)	Pharma (Lec-15) PH 2.1 Adrenergic Drugs-1		Comm. Med - Batch B (SDL) CM 3.2 Water Sampling
	Patho (Lec) PA 6.5 Define and describe embolism	Micro (Lec) MI 1.2 Intro to Virology & Viral infections-2		Path - Batch B (DOAP)Observe a diagnostic cytology and its staining and interpret the specimen PA 8.3
				Comm. Med - Batch A (SDL) CM 3.2 Water Sampling
				AETCOM (CM) Module 2.3: Health care as a right (Student Seminar)
				Micro - Batch A (SGD) (MI 1.1 Lab. Diagnosis of fungal infections)
				Pharma - Batch B (Practical-12) PH 1.5 & 1.6

	and its causes and common types		Inhalational Dosage Forms & device-3	
	Pharma (Lec-16) PH 2.1 Adrenergic Drugs-2	Patho(Lec) PA 6.6 Define and describe Ischaemia/infarction its types, etiology, morphologic changes and clinical effects	Micro- Batch B (SGD) (MI 1.1 Lab. Diagnosis of fungal infections)	
	Surgery (Lec.) SU 2.1/2 Pathophysio, types, cl. Features & management of shock VI(PY,PA)	Pharma (SGD-3) PH 2.1 Adrenergic Drugs-3	Pharma - Batch A (Practical-13) PH 10.9 Calculate the Dosage of drug using appropriate Formula-1	
			Path - Batch A (DOAP) PA 13.5 Perform, Identify and describe the peripheral blood picture in anemia	
			Comm. Med - Batch B (SGD) CM 3.2 National water supply & sanitation programs & Water pollution law	
			Path - Batch B (DOAP) Perform, Identify and describe the peripheral blood picture in anemia PA 13.5	
			Comm. Med - Batch A (SGD) CM 3.2 National water supply & sanitation programs & Water pollution law	
	Obs. & Gyn. (Lec.) OG 7.1 Maternal changes in Pregnancy VI(PY)	Micro (Lec) MI 1.2 Intro to fungus & fungal infecn.-2	2 - 3 PM Patho (SGD) PA 7.2 Describe the molecular basis of cancer	3 - 4 PM Pharma (Lec-17) PH 2.1 Alpha blockers

	Comm. Med. (Lec.) CM 7.6 Screening Tests VI(IM)	Pharma (Lec) PH 1.64& PM 2.5 Drug Development, Clinical Trials-1		AETCOM (CM) Module 2.4: Working in a health care team Tag along - session in Hospital
	Patho (Lec) PA 7.3 Enumerate carcinogens and describe the process of carcinogenesis Embolicism	Micro (LEC) MI 1.2 Intro to Parasites & Parasitic infecn.-1		Micro - Batch A (SGD) MI 1.1 Lab. Diagnosis of viral infections
	Pharma (Lec-18) PH 2.1 Beta blockers	Patho (Lec) PA 7.4 Describe the effects of tumor on the host including paraneoplastic syndrome		Pharma - Batch B (Practical-14) PH 10.9 Calculate the Dosage of drug using appropriate Formula
	Medicine (Lec.) GM 4.4 inflammatory causes of fever	Pharma (Lec-19) PH 2.1, PH 9.7 Drugs used in Glaucoma VI(OP)		Micro- Batch B (SGD) MI 1.1 Lab. Diagnosis of viral infections
	Micro (Lec) MI 1.2 Intro to Parasites & Parasitic infecn.-2	Patho (SGD) PA 7.5 Describe immunology and the immune response to cancer		Pharma - Batch A (Practical-15) PH 10.9 Calculate the Dosage of drug using appropriate Formula including Special population-2
				Path - Batch A (DOAP) PA 14.3 Identify and describe the peripheral smear in microcytic anemia
				Comm. Med - Batch B (SGD) CM 3.2 WHO Guidelines for drinking water - Acceptability aspects
				Path - Batch B (DOAP) 14.3 Identify and describe the peripheral smear in microcytic anemia
				Comm. Med - Batch A (SGD) CM 3.2 WHO Guidelines for drinking water - Acceptability aspects

	Obs. & Gyn. (Lec.) OG 22.1 &22.2 Physiological Vaginal Discharge and discuss Genital Hygiene	Micro (SGD) MI 1.2 Intro to Parasites & Parasitic infecn.-3		2 - 3 PM Patho (SGD) PA 8.1 Describe the diagnostic role of cytology and its application in clinical care	3 - 4 PM Pharma (Lec-20) PH 2.6 Antihistaminics
	Comm. Med.(Lec.) CM 7.7 Investigation of an Epidemic VI(MI/IM)	Pharma (lec-21) PH 2.7 NSAIDs-1		AETCOM (CM) Module 2.4: Working in a health care team Tag along - session in Hospital	
	Patho (Lec) PA 8.2 Describe the basis of exfoliative cytology including the technique & stains used	Mi 1.2,2.1 Normal microbial flora		Micro - Batch A (SGD) MI 1.1 Lab Diag of parasitic infections	
	Pharma (lec-22) PH 2.7 NSAIDs-2	Patho (Lec) PA 9.1 Describe the principles and mechanisms involved in immunity		Pharma - Batch B (Practical-16) PH 10.9 Calculate the Dosage of drug using appropriate Formula including Special population-2	
	Surgery (Lec.) SU 9.2 Early detection & multidisciplinary management of cancer	Pharma (Lec-23) PH 2.8 Gout-1		Micro - Batch B (SGD) MI 1.1 Lab Diag. of parasitic infections	
				Pharma - Batch A (Seminar-2) PH 1.6 Pharmacokinetics	
				Path - Batch A (DOAP) PA 15.3 Identify and describe the peripheral blood picture of macrocytic anemia	
				Comm. Med - Batch B (SDL) CM 3.2 WHO Guidelines for drinking water - Microbiological& Chemical aspects	

	<p>Micro (Lec) MI 1.11Epidemi. of Infect. Dis. VI(CM)</p>	<p>Patho (SGD) PA 9.2Describe the mechanism of hypersensitivity</p>	<p>Path - Batch B (DOAP) PA 15.3 Identify and describe the peripheral blood picture of macrocytic anemia</p>
	<p>Obs. & Gyn. (Lec.) OG 6.1 Diagnosis of Pregnancy</p>	<p>Micro (Lec) MI 11.1 AMR 1 mechanisms and types</p>	<p>Comm. Med - Batch A (SDL) CM 3.2 WHO Guidelines for drinking water - Microbiological & Chemical aspects</p>
	<p>Comm. Med.(Lec.) CM 7.8 Epidemiological studies - 1 VI(IM)</p>	<p>Pharma (Lec-24) PH 2.8 Antirheumatoid Drugs</p>	<p>2 - 3 PM Patho (SGD) PA 9.3 Describe the HLA system and the immune principles</p> <p>Pharma (SGD-4) PH 2.8 Gout-2</p>
	<p>Patho (Lec) PA 9.4 Define autoimmunity. Enumerate autoimmune disorders</p>	<p>Micro (Lec) MI 10.5,11.2 AMR II Intrinsic and acquired, drug resistant microbes in HAI</p>	<p>PM 2.1 (MI) Infection control- Part II Airborne precautions, contact precautions, ICC</p>
	<p>Pharma (Lec-25) PH 2.5 Skeletal Muscle relaxants-1 VI (AS)</p>	<p>Patho (Lec) PA 9.5 Define and describe the pathogenesis of systemic Lupus Erythematosus</p>	<p>Micro - Batch BA(SDL) MI 1.2 Gram's staining</p>
			<p>Pharma - Batch B (Seminar-3) PH 2.1 & 2.3 Antiadrenergic Drugs</p>
			<p>Micro - Batch B (SDL) MI 1.2 Gram's staining</p>
			<p>Pharma - Batch A (SGD-5) PH 1.5 Preparation of ORS from ORS Packet</p>

	<p>Medicine (Lec) GM 4.5 Common Causes of Fever in Malignancy VI(MI)</p>	<p>Pharma (Lec-26) PH 2.5 Skeletal Muscle relaxants-2 VI (AS)</p>		<p>Path - Batch A (DOAP) PA 16.6 Prepare a peripheral blood smear and identify hemolytic anemia from it</p>
	<p>Micro (Lec) MI 11.3 AMR III AMSP</p>	<p>Patho (Lec) PA 9.6 Define and describe the pathogenesis and pathology of HIV and AIDS</p>		<p>Comm. Med - Batch B (SGD) CM 3.2 Radiological aspects & Surveillance of Drinking Water Quality</p>
				<p>Path - Batch B (DOAP) PA 16.6 Prepare a peripheral blood smear and identify hemolytic anaemia from it</p>
				<p>Comm. Med - Batch A (SGD) CM 3.2 Radiological aspects & Surveillance of Drinking Water Quality</p>

	<p>Obs. & Gyn. (Lec.) OG 8.7/8 Vaccination & Investigations in Pregnancy</p>	<p>Micro (LEC) MI 2.1 Intro to Immunity HI(PA)</p>		<p>Patho (SGD) PA 9.7 Define and describe the pathogenesis of other common autoimmune diseases</p>	<p>Pharma (Lec-27) PH 2.5 Local Anesthetics-1</p>
	<p>Comm. Med.(Lec.) CM 7.8 Epidemiological studies - 2 VI(IM)</p>	<p>Pharma (Lec-28) PH 2.5 Local Anesthetics-1</p>		<p>AETCOM (PA) Module 2.8: What does it mean to be family member of a sick patient? (SDL)</p>	

	<p>Patho (Lec) PA 10.1 Define and describe the pathogenesis and pathology of malaria</p>	<p>Micro (SGD) MI 2.2 Antigen HI(PA)</p>		<p>Micro - Batch A (SGD) MI 1.2 Acid fast staining- Batch A</p>
	<p>Pharma (Lec-29) PH 9.1 Immunosuppressant</p>	<p>Patho (Lec) PA 10.2 Define and describe the pathogenesis and pathology of cysticercosis</p>		<p>Pharma - Batch B (SGD-6) PH 1.5 Preparation of ORS from ORS Packet</p>
	<p>Surgery (Lec.) Su 13.1 Immunological basis of organ transplant VI (MI)</p>	<p>Pharma (Lec-30) PH 4.6 Drug acting on RAAS-1</p>		<p>Micro - Batch B (SGD) MI 1.2 Acid fast staining- Batch B</p>
	<p>Micro (LEC) MI 2.2 Antibodies HI(PA)</p>	<p>Patho (SGD) PA 10.3 Define and describe the pathogenesis and pathology of leprosy</p>		<p>Pharma - Batch A (Practical) PH 10.4 Prescription Writing-1</p>
				<p>Path - Batch A (SGD) PA 16.7 Discribe the correct technique to perform a cross match</p>
				<p>Comm. Med - Batch B (SGD) CM 3.1 Air pollution VI(IM/EN)</p>
				<p>Path - Batch B (SGD) PA 16.7 Discribe the correct technique to perform a cross match</p>
				<p>Comm. Med. - Batch A (SGD) CM 3.1 Air pollution VI(IM/EN)</p>

	Obs. & Gyn. (Lec.) OG 9.1 Abortion	Micro (LEC) MI 2.2 Complement System HI(PA)		2 - 3 PM Patho (SGD) PA 10.4 Define and describe the pathogenesis and pathology of common bacterial, viral, protozoal and helminthic diseases	3 - 4 PM Pharma (Lec-31) PH 4.6 Drug acting on RAAS-2
	Com. Med.(Lec.) CM 7.9 Application of Computers in epidemiological studies VI(IM)	Pharma (SDL-1) PH 4.9 Drugs used for Heart Failure-1 VI (IM)		AETCOM (CM) Module 2.4: Working in a health care team (SGD)	
	Patho (Lec) PA 11.1 Describe the pathogenesis and features of common cytogenetic abnormalities and mutations in childhood	Micro (LEC) MI 1.8 Ag-Ab Reactions-1 HI(PA)		Micro Batch A (SGD) MI 1.8- Agglutin & Precipitin Reacn.-1 HI(PA)	Pharma - Batch B (Practical) PH 10.4 Prescription Writing-2
	Pharma (Lec-32) PH 4.9 Drugs used for Heart Failure-1 VI (IM)	Patho (Lec) PA 11.2 Describe the pathogenesis and pathology of tumor and tumourlike conditions in infancy and childhood		Micro Batch B (SGD) MI 1.8- Agglutin & Precipitin Reacn. -1 HI(PA)	Pharma - Batch A (Practical) PH 10.4 Prescription Writing-3
	Medicine (Lec.) GM 7.1/ 7.2 Autoimmune diseases	Pharma (Lec-33) PH 4.8 Antianginal Drugs-1		Path - Batch A (DOAP) PA 19.3 Identify and describe the features of tuberculous lymphadenitis in a gross and microscopic specimen	

	VI(PA)	VI (IM)		Comm. Med - Batch B (SGD) CM 3.1 Tools used in monitoring Air Pollution VI(EN/IM)	
	Obs. & Gyn. (Lec.) OG 27.3 Pelvic Inflammatory Disease	Micro (SGD) MI 1.8 Ag-Ab Reactions-2 HI(PA)		2 - 3 PM Patho (SGD) PA 11.3 Describe the pathogenesis of common storage disorders in infancy and childhood	3 - 4 PM Pharma (Lec-34) PH 4.8 Antianginal Drugs-1 VI (IM)
	Com. Med.(Lec.) CM 8.1 Lab. Tests of Communicable Diseases at PHC HI(MI/PA) VI(IM/PE)	Pharma (Lec-35) PH 4.7 Antihypertensive-1 VI (IM)		AETCOM (PA) Module 2.8: What does it mean to be family member of a sick patient? (Hospital visit & Interviews)	
	Patho (SGD) PA 12.1 Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohol	Micro (SGD) MI 1.8 Ag-Ab Reactions-3 HI(PA)		Micro - Batch A (SGD) MI 1.8 Antigen - Antibody Reactions -2 HI(PA)	
	Pharma (Lec-36) PH 4.7 Antihypertensive-2 VI (IM)	Patho (Lec) PA 12.2 Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation		Pharma - Batch B (Practical) Manual Correction & Logbook Evaluation	
				Micro - Batch B (SGD) MI 1.8 Antigen - Antibody Reactions -2 HI(PA)	
				Pharma - Batch A (Practical) Manual Correction & Logbook Evaluation	

	Surgery (Lec.) SU 5.1 Wound Healing VI(PA)	(Seminar) Cholinergic drugs		Path - Batch B(DOAP) PA 19.3 Identify and describe the features of tuberculous lymphadenitis in a gross and microscopic specimen
	Micro (LEC) MI 1.8 Struc. & Func. of Imm. Sys -1 HI(PA)	Patho (SDL) PA 12.3 Describe the pathogenesis of obesity and its consequences		Comm. Med - Batch B (SGD) CM 3.1 Noise Pollution VI(EN/IM)
	Obs. & Gyn. (Lec.) OG 9.3 MTP	Micro (LEC) MI 1.8 Struc & Func of Imm. Sys -2 HI(PA)		2 - 3 PM Patho (SDL) PA 13.1 Describe hematopoiesis and extramedullary hematopoiesis
	Comm.Med.(Lec.) CM 8.2 Control measures of Non-commun. Ds. VI(IM)	Pharma (Lec-37) PH 4.2 Coagulants		Pharma (SDL-2) PH 4.1 Anemia & Thrombocytopenia
	Patho (Lec) PA 13.2 Describe the role of anticoagulants in hematology	Micro (SGD) MI 1.8 Immune Response-1 CMI HI(PA)		AETCOM (PA) Module 2.8: What does it mean to be family member of a sick patient? Large group discussion with Pt. relatives - 1 Hour Discussion & Closure - 1 Hour
				Micro - Batch A (SDL) MI 1.8 Antigen - Antibody Reactions HI(PA)
				Pharma - Batch B (Practical) Manual Correction & Logbook Evaluation

	Pharma (Lec-38) PH 4.2 Anticoagulants-1	Patho (Lec) PA 13.3 Define and classify anemia		Micro - Batch B (SDL) MI 1.8 Antigen - Antibody Reactions HI(PA)
	Medicine (Lec.) GM 9.1/2 Anemia VI(PA)	Pharma (Lec-39) PH 4.2 Anticoagulants-2		Pharma - Batch A (Practical) Manual Correction & Logbook Evaluation
	Micro (SGD) MI 1.8 Immune Response-2 HMI HI(PA)	Patho (SGD) PA 13.4 Enumerate and describe the investigation of anemia		Path - Batch B (DOAP) PA 19.5 Identify and describe the features of Hodgkin's lymphoma in a gross and microscopic specimen
				Comm. Med - Batch B (SDL) CM 3.1 Environment & Health
	Obs. & Gyn. (Lec.) OG 12.1 Eclampsia HI(IM)	Micro (Lec) MI 1.10 Hypersensitivity Reactions - 1 VI(PE)		Path - Batch A (DOAP) PA 19.7 Identify and describe the gross specimen of an enlarged spleen
				Comm. Med - Batch B (SDL) CM 3.1 Environment & Health
				2 - 3 PM Patho (SGD) PA 14.1 Describe iron metabolism
				3 - 4 PM Pharma (SGD) PH 4.2 Anticoagulants-3
	Comm.Med.(Lec.) CM 8.3 National Health programme VI(PE/IM)	Pharma (SDL-3) PH 4.10 Antiarrhythmic drugs		MICROBIOLOGY MI 1.2- Grams/ Zn and Stool Microscopy

	<p>Patho (Lec) PA 14.2 Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia</p>	<p>Micro (Lec) MI 1.10 Hypersensitivity Reactions - 2 VI(PE)</p>		<p>Micro - Batch -A (SDL) MI 1.2 Acid fast staining</p>	
	<p>Pharma (Lec-40) PH 4.11 Drugs used for Dyslipidaemias-1</p>	<p>Patho (Lec) PA 15.1 Describe the metabolism of Vitamin B12 and the etiology and pathogenesis of B12 deficiency</p>		<p>Pharma - Batch B (Practical) PH10.4 Prescriptions Writing-3</p>	
	<p>Surgery (Lec.) SU 5.2/3 Types of Wound – Plan & Management</p>	<p>Pharma (Lec-41) PH 4.11 Drugs used for Dyslipidaemias-2</p>		<p>Micro - Batch -B (SDL) MI 1.2 Acid fast staining</p>	
				<p>Pharma - Batch A (Practical) PH10.4 Prescriptions Writing-4</p>	
				<p>Path - Batch B (DOAP) PA 19.7 Identify and describe the gross specimen of an enlarged spleen</p>	
				<p>Comm. Med - Batch B (SGD) CM 3.1 Atmospheric Pressure & Air Temperature VI(EN/IM)</p>	
	<p>Micro (Lec) MI 1.10 Autoimmune Disorders VI(PE)</p>	<p>Patho (SGD) PA 15.2 Describe laboratory investigations of macrocytic anemia</p>		<p>Path - Batch A (DOAP) PA 20.1 Describe the features of plasma cell myeloma</p>	
				<p>Comm. Med - Batch A (SGD) CM 3.1 Atmospheric Pressure & Air Temperature VI(EN/IM)</p>	
	<p>Obs. & Gyn. (Lec.) OG 12.2 Anemia in Pregnancy-1 HI(IM)</p>	<p>Micro (Lec) MI 1.10 Immunodeficiency Diseases VI(PE)</p>		<p>2 - 3 PM Patho (SDL) PA 15.4 Distinguishing features of megaloblastic and non-megaloblastic macrocytic anemia</p>	<p>3 - 4 PM Pharma (Lec-42) PH 4.3 Fibrinolytic & Antifibrinolytic agents VI (IM)</p>

	Comm.Med.(Lec.) CM 8.4 Control of Epidemic VI (PE/IM)	Pharma (Lec-43) PH 4.4 Antiplatelets		AETCOM (MI) Module 2.2 The foundations of bioethics Large group session
	Patho (Lec) PA 16.1 Define and classify hemolytic anemia	Micro (LEC) MI 8.5 Hosp. Acquired Infections VI(CM/IM)		Micro - Batch -A (SDL) MI 8.7 Hand Hygiene & PPE VI(CM/SU)
	Pharma (Lec-44) PH 4.5 Diuretics & Antidiuretics-1	Patho (Lec) PA 16.2 Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia		Pharma - Batch B (Seminar-4) PH 1.12 Pharmacovigilance
	Medicine (Lec.) GM 9.6/13 Diagnostic Workup & replacement therapy of Anemia VI(PA)	Pharma (Lec-45) PH 4.5 Diuretics & Antidiuretics-2		Micro - Batch -B (SDL) MI 8.7 Hand Hygiene & PPE VI(CM/SU)
	Micro (SGD) MI 8.6 & PM 2.1 Infection Control VI(CM/IM)	Patho (SGD) PA 16.3 Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia		Pharma - Batch A (Seminar-5) ADRs
				Path - Batch B 20.1 DOAP Describe the features of plasma cell myeloma
				Comm. Med - Batch B (SGD) CM 3.1 Effect of Heat & Cold VI (EN/IM)
				Path - Batch A (SGD) PA 21.3 Differentiate platelet from clotting disorders based on the clinical and hematologic features
				Comm. Med - Batch A (SGD) CM 3.1 Effect of Heat & Cold VI (EN/IM)

	<p>Obs. & Gyn. (Lec.) OG 12.2 Anemia in Pregnancy-2 HI(IM)</p>	<p>Micro (Lec) MI 2.1 Rheumatic fever &RHD HI(PA) VI(IM)</p>		<p>2-3 PM Patho (SGD) PA 16.4Describe the etiology pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia</p>	<p>3 – 4 PM Pharma (SGD-7) PH 3.1 General Anesthetics-1 VI (AS)</p>
	<p>Comm. Med.(Lec.) CM 8.5 Control measures of disease at Community level VI(PE/IM)</p>	<p>Pharma (Lec-46) PH 3.1 General Anesthetics- 2 VI (AS)</p>		<p>PM 2.2 (Com. Med.) Emerging & Reemerging infections</p>	
	<p>Patho (Lec) PA 16.5 Describe the peripheral blood picture in different hemolytic anaemias</p>	<p>Micro (SGD) MI 2.1 Rheumatic fever & RHD HI(PA) VI(IM)</p>		<p>Micro - Batch -A (SGD) MI 2.3 Lab Diagnosis of Rheumatic fever & RHD HI(PA) VI(IM)</p>	
	<p>Pharma (Lec-47) PH 3.3 Drugs used in epilepsy-1 VI (PY.IM)</p>	<p>Patho (Lec) PA 17.1Enumerate the etiology, pathogenesis and findings in aplastic anemia</p>		<p>Pharma - Batch B (SGD-8) PH10.4 Prescriptions Writing-5</p>	
				<p>Micro - Batch -B (SGD) MI 2.3 Lab Diagnosis of Rheumatic fever & RHD HI(PA) VI(IM)</p>	
				<p>Pharma - Batch A (SGD-9) PH10.4 Prescriptions Writing-6</p>	

	<p>Surgery (Lec.) SU 9.1 Investigations in a surgical patient VI (BI, PA, MI)</p>	<p>Pharma (Lec-48) PH 3.3 Drugs used in epilepsy-2 VI (PY.IM)</p>		<p>Path – B, Batch (SGD) PA 21.3 Differentiate platelet from clotting disorders based on the clinical and hematologic features</p>
				<p>Comm. Med - Batch B (SDL) CM 3.1 Humidity & Precipitation measurement VI(IM)</p>
	<p>Micro (Lec) MI 2.2 Infective Endocarditis HI(PA) VI(IM)</p>	<p>Patho (SGD) PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy</p>		<p>Path - Batch A (SGD) PA 22.2 Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing</p>
				<p>Comm. Med - Batch A (SDL) CM 3.1 Humidity & Precipitation measurement VI(IM)</p>
	<p>Obs. & Gyn. (Lec.) OG 12.4 Heart Ds. In Pregnancy HI(IM)</p>	<p>Micro (Lec) MI 1.1 Misc. Bloodstream infections-1 Leptospirosis VI (IM)</p>		<p>2 - 3 PM Patho (SGD) PA 18.1 Enumerate and describe the causes of leucocytosis leucopenia lymphocytosis and leukemoid reactions</p>
				<p>3 - 4 PM Pharma (Lec-49) PH 3.7 Drugs used Parkinsonism-1</p>
	<p>Com.Med.(Lec.) CM 8.6 Disease Surveillance</p>	<p>Pharma (Lec-50) PH 3.7 Drugs used Parkinsonism-2 VI (IM)</p>		<p>PM 2.2 (Com. Med.) Emerging & Reemerging infections, early identification</p>
	<p>Patho (Lec) PA 18.2 Describe the etiology, genetics, pathogenesis classification, features, hematologic features of acute and chronic leukemia</p>	<p>Micro (Lec) MI 1.1 Misc. Bloodstream infections-2 Borreliosis VI (IM)</p>		<p>Micro – Batch A (SGD) MI 2.2 Lab diagnosis of Leptospirosis HI (PA) VI (IM)</p>
				<p>Pharma - Batch B (Practical) PH10.4 Prescriptions Writing-7</p>

	<p>Pharma (Lec-51) PH 3.4 Opioids-1 VI (PS)</p>	<p>Patho (Lec) PA 19.1 Enumerate the causes and describe the differentiating features of lymphadenopathy</p>		<p>Micro- Batch B (SGD) MI 2.2 Lab diagnosis of Leptospirosis HI (PA) VI (IM)</p>
	<p>Medicine (Lec.) GM 13.15 Common tests for malignancies VI(PA)</p>	<p>Pharma (Lec-52) PH 3.4 Opioids-2 VI (PS)</p>		<p>Pharma - Batch A (Practical) PH10.4 Prescriptions Writing-8</p>
	<p>Micro (SGD) MI 1.1 Viral Hemorrhagic fever-1 (Dengue) VI (IM)</p>	<p>Patho (SGD) PA 19.2 Describe the pathogenesis and pathology of tuberculous lymphadenitis</p>		<p>Path - Batch B (SGD) PA 22.2 Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing</p>
	<p>Obs. & Gyn. (Lec.) OG 27.2 Genital TB</p>	<p>Micro (SGD) MI 1.1 Viral Hemorrhagic fever-2 (Chikungunya) VI (IM)</p>		<p>Comm. Med - Batch B (SDL) CM 3.5 Housing & Its Effects</p>
				<p>Path - Batch A (DOAP) PA 23.1 Describe abnormal urinary findings in disease states and identify and describe common urinary abnormalities in a clinical specimen</p>
				<p>Comm. Med - Batch A (SDL) CM 3.5 Housing & Its Effects</p>
			<p>2 - 3 PM Patho (SGD) 19.4 Describe and discuss the pathogenesis, pathology and the differentiating features of Hodgkin's and non-Hodgkin's lymphoma</p>	<p>3 - 4 PM Pharma (SGD-10) PH 3.5 Drugs used for Psychosis-1 VI (PS)</p>

	<p>Comm.Med. (Lec.) CM 8.1 Epi., diagnosis & control measures of TB VI (IM,PE) HI (MI, PA)</p>	<p>Pharma (Lec-53) PH 3.5, Drugs used for Psychosis-2 VI (PS)</p>		<p>PM 2.2 (Com. Med.) Emerging & Reemerging infections – Control of new infections</p>
	<p>Patho (Lec) PA 19.6 Enumerate and differentiate the causes of splenomegaly</p>	<p>Micro (Lec) MI 1.1 Viral Hemorrhagic fever-3 (Filoviridae) VI (IM)</p>		<p>Micro – Batch A (SGD) MI 1.1 Lab diagnosis of Viral Hemorrhagic fever-1 (Dengue) VI (IM)</p>
	<p>Pharma (Lec-54) PH 3.5 Drugs used for Depression-1 VI (PS)</p>	<p>Patho(Lec) PA 21.1 Describe normal hemostasis</p>		<p>Pharma - Batch B (Practical) PH 10.6 Critical appraisal of Prescription/ Problem solving exercise -1</p>
				<p>Micro – Batch B (SGD) MI 1.1 Lab diagnosis of Viral Hemorrhagic fever-1 (Dengue) VI (IM)</p>
				<p>Pharma - Batch A (Practical) PH 10.6 Critical appraisal of Prescription/ Problem solving exercise-2</p>

	Pharma (Lec-57) PH 3.8 Ethanol & Methanol Poisoning VI (IM)	Patho (Lec) PA 22.1 Classify and describe blood group systems (ABO and RH)		Micro Batch B (SGD) MI 2.5 Lab Diagnosis of malaria HI(PA) VI(IM)
				Pharma Batch A (Practical) Manual Correction and log book Evaluation
	Medicine (Lec.) GM 9.11 Describe the national programs for anemia prevention	Pharma (Lec-58) PH 3.9 Drug addiction & stimulants		Path - Batch B (DOAP) PA 23.3 Describe and interpret the abnormalities in a panel containing semen analysis, thyroid function tests, renal function tests or liver function tests
				Comm. Med - Batch B (SGD) CM 5.1 Nutrition & Macro & Micronutrients VI (PE/IM)
	Micro (Lec) MI 2.4 Parasites causing Anemia HI(PA) VI(IM)	Patho (SGD) PA 22.4 Enumerate blood components and describe their clinical uses		Path - Batch A (SGD) PA 24.3 Describe and identify the microscopic features of peptic ulcer
				Comm. Med - Batch A (SGD) CM 5.1 Nutrition & Macro & Micronutrients VI(PE/IM)
	Obs. & Gyn. (Lec.) OG 12.5 UTI HI(IM)	Micro (Lec) MI 2.5 Fiarial Worms HI(PA) VI(IM))		2 - 3 PM Patho(SGD) PA 22.5Enumerate and describe infections transmitted by blood transfusion
				3 - 4 PM Pharma (Lec-59) PH 6.1 Drug used in Peptic ulcer-1 HI(MI/PA)VI (IM)

	Com. Med.(Lec.) CM 6.2 Statistical Data VI(PE/IM)	Pharma (Lec-60) PH 6.1 Drug used in Peptic ulcer-2 HI(MI/PA)VI (IM)		PM 2.4 (Com. Med.) Vaccination strategies & implementation
	Patho (Lec) PA 22.6Describe transfusion reactions and enumerate the steps in the investigation of a transfusion reaction	Micro (Lec) MI 2.5 Schistosomes HI(PA) VI(IM)		Micro Batch A (SGD) MI 2.5 Lab Diagnosis of filariasis HI(PA) VI(IM))
	Pharma (Lec-61) PH 6.2 Emetic & Antiemetics-1 VI(IM)	Patho(Lec) PA 22.7Enumerate the indications and describe the principles and procedure of autologous transfusion		Pharma - Batch B (Practical) Manual Correction and log book Evaluation
	Surgery (Lec.) SU 3.1 Blood & Blood Products VI(PA)	Pharma (Lec-62) PH 6.2 Emetic & Antiemetics-1 VI(IM)		Micro Batch B (SGD) MI 2.5 Lab Diagnosis of filariasis HI(PA) VI(IM))
				Pharma - Batch A (Practical) Manual Correction and log book Evaluation
				Path - Batch B (SGD) PA 24.3Describe and identify the microscopic features of peptic ulcer
				Comm. Med - Batch B (SGD) CM 5.1 Nutritional profile of Cereals, Millets & Legumes VI(PE/IM)
	Micro (Lec) MI 3.1 Bacteria causing Diarrhoea - Introduction & E. coli HI(PA) VI(IM/PE)	Patho (SGD) PA 23.2 Describe abnormal findings in body fluids in various disease states		Path - Batch A (DOAP) PA 25.6Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from non-obstructive jaundice based on clinical features and liver function tests
				Comm. Med - Batch A (SGD) CM 5.1 Nutritional profile of Cereals, Millets & Legumes VI(PE/IM)

	Obs. & Gyn. (Lec.) OG 10.2 Blood Transfusion VI(PA)	Micro (Lec) MI 3.1 Bacteria causing Diarrhoea - E. coli HI(PA) VI(IM/PE)		2 - 3 PM Patho (SGD) PA 24.1 Describe the etiology, pathogenesis, pathology and clinical features of oral cancers	3 - 4 PM Pharma (SDL-4) PH 6.3, PH 6.5 Drugs used in Diarrhoea & IBD-1 HI(MI) VI(M)
	Comm. Med. (Lec.) CM 8.1 Epi., lab test & control of diarrheal dis. VI(MI/PA)	Pharma (SGD-12) PH 6.3, PH 6.5 Drugs used in Diarrhea & IBD-2 HI(MI) VI(M)		PM 2.4 (Com. Med.) Vaccination strategies & implementation	
	Patho(Lec) PA 24.2 Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease	Micro (Lec) MI 3.1 Bacteria causing Diarrhoea - Vibrio HI(PA) VI(IM/PE)		Micro Batch A (SGD) MI 3.2- Lab diagnosis of Diarrhea / Dysentery VI(PE/IM)	
	Pharma (Lec-63) PA 6.4 Drugs used in Constipation VI(M)	Patho(Lec) PA 24.4 Describe etiology and pathogenesis and pathologic features of carcinoma of the stomach		Pharma - Batch B (Practical) Manual Correction and log book Evaluation	
	Micro (Lec) MI 3.1 MI 3.1 Viruses causing Diarrhoea	Patho (SGD) PA 24.5 Describe etiology and pathogenesis and		Micro Batch B (SGD) MI 3.2- Lab diagnosis of Diarrhoea VI(PE/IM)	
				Pharma - Batch A (Practical) Critical appraisal of Prescription/ Problem solving exercise-4	
				Path - Batch B DOAP PA 25.6 Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from non-obstructive jaundice based on clinical features and liver function tests	

	HI(PA) VI(IM/PE)	pathologic features of Tuberculosis of the intestine		Comm. Med - Batch B (SDL) CM 5.1 Nutritional value of Food
	Obs. & Gyn. (Lec.) OG 22.2 Vaginal Candidiasis	Micro (Lec) MI 3.1 Bacteria causing APD & Ca Stomach- H. pylori HI(PA) VI(IM/PE)		2 - 3 PM Patho(SGD) PA 24.6 Describe and etiology and pathogenesis and pathologic and distinguishing features of Inflammatory bowel disease
	Comm. Med.(Lec.) CM 6.4 Common sampling Techniques VI(PE/IM)	Pharma (Lec-64) PH 5.1 Drugs used in Bronchial Asthma-1 VI (CT)		3 - 4 PM (SGD-13) PH 5.2 Cough VI (CT)
				MICROBIOLOGY MI 1.2- Grams/ Zn and Stool Microscopy

	Patho (SGD) PA 24.7 Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon	Micro (Lec) Bacteria causing Dysentery – Shigella /Campylo HI(PA) VI(IM/PE)		Micro Batch A (SGD) MI 3.2- Lab diagnosis of Dysentery VI(PE/IM)
	Pharma (Lec-65) PH 5.1 Drugs used in Bronchial Asthma-2 VI (CT)	Patho(Lec) PA 25.1 Describe bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia		Pharma Batch B (Practical) PH 10.6 Critical appraisal of Prescription/ Problem solving exercise-5
				Micro Batch B (SGD) MI 3.2- Lab diagnosis of Dysentery VI(PE/IM)
				Pharma Batch A (Practical) PH 10.6 Critical appraisal of Prescription/ Problem solving exercise-6

	<p>Medicine (Lec.) GM 16.13 Treatment of Parasitic Diarrhoea VI(PH/MI)</p>	<p>Pharma (SGD-14) PH 8.1,PH 8.2 General Principles of Antimicrobial</p>		<p>Path - Batch A (DOAP) PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes</p>
				<p>FMT - Batch B (SGD) FM 1.2 History of Forensic Medicine</p>
	<p>Micro (Lec) MI 3.1 Parasites causing Dysentery- Amoebiasis HI(PA) VI(IM/PE)</p>	<p>Patho(Lec) PA 25.2Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences</p>		<p>Path - Batch B (DOAP) PA 27.8Interpret abnormalities in cardiac function testing in acute coronary syndromes</p>
				<p>FMT - Batch A (SGD) FM 1.2 History of Forensic Medicine</p>
	<p>Obs. & Gyn. (Lec.) OG 12.8 Rh Pregnancy</p>	<p>Micro (SGD) MI 3.1 Parasites causing Dysentery-2 HI(PA) VI(IM/PE)</p>		<p>2 - 3 PM Patho (SGD) PA 25.3Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on the clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis</p>
				<p>3 - 4 PM Pharma (Lec-66) PH 8.3 Sulphonamides VI(IM)</p>
	<p>FMT. (Lec.) FM 1.1 Basics of Forensic Medicine</p>	<p>Pharma (Lec-67) PH 8.3 Quinolones</p>		<p>AETCOM (PH) Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Introduction - 1 Hour Case Intro. - 1 Hour</p>

	<p>Patho (SGD) PA 25.4 Alcoholic liver disease including cirrhosis</p>	<p>Micro (Lec) MI 3.3 Enteric Fever HI(PA/PH) VI(IM)</p>		<p>Micro Batch A (SGD) MI 3.4- Lab diagnosis of Enteric Fever HI(PA) VI(IM)</p>	
	<p>Pharma (Lec-68) PH 8.3 Beta lactams-1</p>	<p>Patho (Lec) PA 25.5 Describe the etiology, pathogenesis and complications of portal hypertension</p>		<p>Pharma - Batch B (Tutorial) PH 10.6 Critical appraisal of Prescription/ Problem solving exercise-7</p>	
	<p>SURGERY (Lec.) SU 28.10 Hepatic injuries</p>	<p>Pharma (Lec-69) PH 8.3 Beta lactams-2</p>		<p>Micro Batch B (SGD) MI 3.4- Lab diagnosis of Enteric Fever HI(PA) VI(IM)</p>	
				<p>Pharma - Batch A (Tutorial) PH 10.6 Critical appraisal of Prescription/ Problem solving exercise-8</p>	
				<p>Path - Batch A (DOAP) PA 31.3 Describe and identify the morphologic and microscopic features of carcinoma of the breast</p>	
				<p>FMT - Batch B (SGD) FM 1.6 / 7 Describe Offences in Court / Dying Delcaration & Dying Deposition</p>	
	<p>Micro (Lec) MI 3.7 Viral Hepatitis -1 HI(PA) VI(IM) HI(PA/PH) VI(IM)</p>	<p>Patho (Lec) PA-26.1 Define and describe the etiology, types, pathogenesis, stages, morphology and complications of pneumonia</p>		<p>Path - Batch B (DOAP) PA 31.3 Describe and identify the morphologic and microscopic features of carcinoma of the breast</p>	
				<p>FMT - Batch A (SGD) FM 1.6 / 7 Describe Offences in Court / Dying Delcaration & Dying Deposition</p>	
	<p>Obs. & Gyn. (Lec.) OG 12.6 Liver disease in pregnancy HI(IM)</p>	<p>Micro (Lec) MI 3.7 Viral Hepatitis -2 HI(PA) VI(IM)</p>		<p>2 - 3 PM Patho (SGD) PA 26.2 Describe the etiology, gross and microscopic appearance and complications of lung abscess</p>	<p>3 - 4 PM Pharma (SGD-12) PH 8.3 Cephalosporins</p>

	FMT.(Lec.) FM 2.1 Death & its Types VI(PA)	Pharma (SGD) PH 8.3 Tetracyclines		AETCOM (PH) Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making Anchoring Lec. - 1 Hour Case resolution - 1 Hour
	Patho (Lec) PA 26.3 Define and describe the etiology, types, pathogenesis, stages, morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis	Micro (Lec.) MI 6.1 URTI - Sore Throat VI(IM)		Micro Batch A (SGD) MI 3.8- Lab diagnosis of Viral Hepatitis HI(PA) VI(IM)
	Pharma (Lec-70) PH 8.3 Aminoglycosides-1 VI(MI)	Patho(Lec) PA 26.4 Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis		Pharma - Batch B (Seminar-6) Treatment of epilepsy
	Medicine (Lec.) GM 5.3 Viral hepatitis VI (PA, MI)	Pharma (Lec-71) PH 8.3 Aminoglycosides-2 VI(MI)		Micro Batch B (SGD) MI 3.8- Lab diagnosis of Viral Hepatitis HI(PA) VI(IM)
				Pharma - Batch A (Seminar-7) Treatment of epilepsy
				Path - Batch A (DOAP) PA 34.4 Identify, distinguish and describe common tumors of the skin
				FMT - Batch B (SGD) FM 1.8/9 Orders & Documentation related to Medicolegal Practice VI(PE/IM/SU/RD)

	Obs. & Gyn. (Lec.) OG 9.4 Acute abdomen in early pregnancy (with a focus on ectopic pregnancy)	Micro (Lec) MI 6.1 URTI – Viruses - 1 VI(IM)		2 - 3 PM Patho (SGD) PA 26.5 Define and describe the etiology, types, exposure, environmental influence, pathogenesis, stages, morphology, microscopic appearance and complications of Occupational lung disease	3 - 4 PM Pharma (SGD-16) PH 8.3 Macrolides-1
--	---	---	--	--	---

		FMT. (Lec.) FM 2.2 Natural & Unnatural Deaths VI(PA)	Pharma (Lec-72) PH 8.3, PH 8.4 Macrolides 2		AETCOM (PH) Module 2.6: Bioethics continued – Case studies on patient autonomy and decision making Introduction to case - 1 Hour Anchoring Lecture - 1 Hour
		Patho(Lec) PA 26.6 Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, stages, morphology, microscopic appearance, metastases and complications of tumors of the lung and pleura	Micro (Lec.) MI 6.1 URTI – Viruses-2 VI(IM)		Micro Batch A (SGD) MI 6.3 - Lab diagnosis of sore throat VI(IM)
		Pharma (SDL-5) PH 8.5 Antitubercular-1	Patho(Lec) PA 26.7 Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, morphology, microscopic appearance and complications of mesothelioma		Pharma - Batch B (Practical) PH 1.8 Effect of drug on blood pressure using CAL
		Surgery (Lec) SU 17.9 Management of Chest Injuries	Pharma (Lec-73) PH 8.5 Antitubercular-2		Micro Batch B (SGD) MI 6.3 - Lab diagnosis of sore throat VI(IM)
					Pharma - Batch A (Practical) PH 1.8 Effect of drug on blood pressure using CAL
					Path - Batch B (DOAP) PA 34.4 Identify, distinguish and describe common tumors of the skin
					FMT - Batch B (SGD) FM 1.10/11 Cause of Death & Death Certificate as per ICD 10 Document

	<p>Micro (Lec) MI 6.1 URTI – Diphtheria VI(IM)</p>	<p>Patho (SGD) PA 27.1 Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis</p>		<p>Path - Batch A (DOAP) PA 35.3 Identify the etiology of meningitis based on given CSF parameters</p>	
				<p>FMT - Batch A (SGD) FM 1.10/11 Cause of Death & Death Certificate as per ICD 10 Document</p>	
	<p>Obs. &Gyn. (Lec.) OG 9.6 Hyperemesis gravidarum</p>	<p>Micro. (Lec.) MI 6.1 URTI – Pertusis VI(IM)</p>		<p>2 -3 PM Patho (SGD) PA 27.2 Describe the etiology, dynamics, pathology types and complications of aneurysms including aortic aneurysms</p>	<p>3 – 4 PM Pharma (SGD-17) PH 8.6 Drug used in Leprosy</p>
	<p>FMT. (Lec.) FM 2.5 Modes of Death VI(PA/PS)</p>	<p>Pharma (SDL-6) PH 8.3 Antiamoebics-1</p>		<p>MICROBIOLOGY MI 1.2- Grams/ Zn and Stool Microscopy</p>	
	<p>Pharma (Lec-74) PH 8.3 Antiamoebics-2 VI (CT)</p>	<p>Patho (SGD) PA 27.3 Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure</p>		<p>Batch B MI 6.3 - Lab diagnosis of diphtheria/pertusis VI(IM)-</p>	
				<p>Pharma – Batch A (Practical) PH 1.5 Demonstrate the various route of drug administration in simulated environment</p>	
	<p>Medicine (Lec) GM 3.1/2/3 Pneumonia VI(MI)</p>	<p>Pharma (SGD-18) Antiamoebics-3</p>		<p>Path - Batch B(DOAP) PA 35.3 Identify the etiology of meningitis based on given CSF parameters</p>	

				FMT - Batch B (SGD) FM 2.6/7 Death & Survivorship Suspended Animation
	Micro (SGD) MI 6.1 LRTI –Pneumonia VI(IM)	Patho (SGD) PA 27.4 Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications of rheumatic fever		Path - Batch A (SGD) REVISION
	Obs. & Gyn. (Lec.) OG 11.1 Multiple Pregnancy	Micro.(Lec.) MI 6.1 LRTI - TB-1 VI(IM)		FMT - Batch A (SGD) FM 2.6/7 Death & Survivorship Suspended Animation
	FMT. (Lec.) FM 2.3 Issues related to Sudden Natural Deaths	Pharma (SGD-19) PH 8.9 Anthelmintics VI (MI)	2 - 3 PM Patho (SGD) PA 27.5 Describe the epidemiology, risk factors, etiology, pathophysiology, pathology, presentations, gross and microscopic features, diagnostic tests and complications of IHD	Pharma (Lec-75) PH8.8 Antifungal
				AETCOM (PH) Module 2.6: Bioethics continued – Case studies on patient autonomy and decision making (SDL)

	<p>Patho(Lec) PA 27.6 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of infective endocarditis</p>	<p>Micro. (Lec.) MI 6.1 LRTI - TB-2 VI(IM)</p>		<p>Micro Batch A (SGD) MI 6.2 - Lab diagnosis of Pul. TB VI(IM)</p>
	<p>Pharma (SGD-20) PH 8.10 Antiviral-1</p>	<p>Patho(Lec) PA 27.7 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of pericarditis and pericardial effusion</p>		<p>Pharma - Batch B (Practical) PH 1.5 Demonstrate the various route of drug administration in simulated environment</p>
	<p>Surgery (Lec) SU 26.4 Tumours of lung</p>	<p>Pharma (SGD-22) PH 8.10 Antiviral-2</p>		<p>Micro Batch B (SGD) MI 6.2 - Lab diagnosis of Pul. TB VI(IM)</p>
	<p>Micro (Lec) MI 6.1 LRTI -Atypical Pneumonia HI(IM)</p>	<p>Patho (SGD) PA 27.9 Classify and describe the etiology, types, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of cardiomyopathies</p>		<p>Pharma - Batch A (SGD-21) PH 10.1 Source of drug information</p>
				<p>Path - Batch B (SGD) REVESION</p>
				<p>FMT - Batch B (SGD) FM 2.9/10 Purification / Mummification / Estimation of Time Since Death</p>
				<p>Path - Batch A (SGD) REVESION</p>
				<p>FMT - Batch A (SGD) FM 2.9/10 Purification / Mummification / Estimation of Time Since Death</p>

	<p>Obs. & Gyn. (Lec.) OG 13.1 Enumerate and discuss the diameters of maternal pelvis and types</p>	<p>Micro. (Lec.) MI 6.1 Viral LRTI VI(IM)</p>		<p>2 - 3 PM Patho (SDL) PA 27.10 Describe the etiology, pathophysiology, pathology features and complications of syphilis on the cardiovascular system</p>	<p>3 - 4 PM Pharma (SGD-23) PH 8.11 Anticancer-1</p>
	<p>FMT.(Lec.) FM 2.8 Postmortum Changes 1</p>	<p>Pharma (Lec-76) PH 8.11 Anticancer-2</p>		<p>AETCOM (PH) Module 2.6: Bioethics continued – Case studies on patient autonomy and decision making Discussion & Case Closure</p>	
	<p>Patho(Lec) PA 28.1 Describe the normal histology of the kidney</p>	<p>Micro (Lec) MI 6.1 LRTI - COVID VI(IM)</p>		<p>Micro Batch A (SGD) PM-2.3- Sample collection, lab diagnosis of Covid VI(IM)</p>	<p>Pharma Batch B (SGD-24) PH 10.1 Source of drug information</p>
	<p>Pharma (SDL-7) PH 7.1 Drugs used in Diabetes mellitus-1</p>	<p>Patho (SGD) PA 28.2 Define, classify and distinguish the clinical syndromes and describe the etiology, pathogenesis, pathology, morphology, clinical and laboratory and urinary findings, complications of renal failure</p>		<p>Micro Batch B (SGD) PM-2.3- Sample collection, lab diagnosis of Covid VI(IM)</p>	<p>Pharma - Batch A (Seminar-8) PH 5.1 Bronchial Asthma</p>

	<p>Medicine (Lec) GM 3.15/16/17/18 Supportive Therapy of Pneumonia</p>	<p>Pharma (Lec-77) PH 7.1 Drugs used in Diabetes mellitus-2</p>		<p>Path - Batch B (SGD) REVISION</p>	
	<p>Micro (Lec) MI 6.1 LRTI - Hospital Ac. Pneumonia-1 VI(IM)</p>	<p>Patho (Lec) PA 28.3 Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of acute renal failure</p>		<p>FMT - Batch B (SGD) FM 2.14/15 Postmortum Examination/ Protocols for Medicolegal Autopsies</p>	
	<p>Obs. &Gyn.(LEC) OG 13.2 Discuss the mechanism of normal labor</p>	<p>Micro (SGD) MI 6.1 LRTI - Hospital Ac. Pneumonia-2 VI(IM)</p>		<p>2 - 3 PM Patho (SGD) PA 28.4 Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings progression and complications of chronic renal failure</p>	<p>3 - 4 PM Pharma (Tutorial-2) PH 7.1 Drugs used in Diabetes mellitus-3</p>
	<p>FMT.(Lec.) FM 2.8 Postmortum Changes 2</p>	<p>Pharma (Tutorial-3) PH 7.1 Drugs used in Diabetes mellitus-3</p>		<p>AETCOM (PH) Module 2.7: Bioethics continued – Case studies on patient autonomy and decision making Introduction to case - 1 Hour Anchoring Lecture - 1 Hour</p>	

	<p>Patho (Lec) PA 28.5 Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis</p>	<p>Micro (Lec.) MI 6.1 LRTI - Fungal Pneumonia VI(IM)</p>		<p>Micro Batch A (SDL) PM-2.3 - Sample collection, lab diagnosis of Covid VI(IM)</p>
	<p>FMT.(Lec.) FM 2.18 Crime Scene Investigations</p>	<p>Patho(Lec) PA 28.6 Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of IgA nephropathy</p>		<p>Pharma Batch B (Seminar-9) Angina Pectoris</p>
	<p>Surgery (Lec.) SU 26.1 Role of surgery in heart diseases</p>	<p>Pharma (Lec-78) PH 7.1 Drugs used in Diabetes mellitus-3</p>		<p>Micro Batch B (SDL) PM-2.3 - Sample collection, lab diagnosis of Covid VI(IM) VI(IM)</p>
				<p>Pharma Batch A (Practical) PH1.10.2 Critical appraisal of drug advertisement/promotional literature</p>
				<p>Path - Batch B (SGD) REVESION</p>
				<p>FMT - Batch B (SDL) FM 2.16 Examination of Mutilated Bodies</p>
	<p>Micro (LEC) MI 7.3 UTI VI(IM)</p>	<p>Patho(Lec) PA 28.7 Enumerate and describe the findings in glomerular manifestations of systemic disease</p>		<p>Path - Batch A(SGD) REVESION</p>
				<p>FMT - Batch A (SDL) FM 2.16 Examination of Mutilated Bodies</p>

	Obs. & Gynae. (LEC) OG 22.2 Pathological Vaginal discharge	Micro (Lec) MI 7.2 STD - 1 (Gonococci) VI(DR/OG)		2 - 3 PM Path (SGD) PA 28.8 Enumerate and classify diseases affecting the tubular interstitium	Pharma (SDL-8) PH 7.2 Drugs used in osteoporosis VI(OP)
	FMT.(Lec.) FM 2.11/12 Autopsy / Legal requirements VI(PA)	Pharma (SDL-9) PH 7.3 Drugs used in Thyroid Disorder-1		MICROBIOLOGY MI 6.2 / 6.3 –URTI & LRTI – Grams Stain / Zn stain	
	Patho (Lec.) PA 28.9 Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of acute tubular necrosis	Micro (Lec) MI 7.2 STD - 2 (NGU) VI(DR/OG)		Micro Batch A (SGD) MI 7.3 - Lab diagnosis of UTI VI(IM)	
	Pharma (Lec-79) PH 7.3 Drugs used in Thyroid Disorder-2	Patho (SGD) PA 28.10 Distinguishing features progression and complications of acute and chronic pyelonephritis and reflux nephropathy		Pharma - Batch B (Practical) PH1.10.2 Critical appraisal of drug advertisement/promotional literature	
	Medicine (Lec.) GM 1.1 Common causes of heart disease VI(PY/PA)	Pharma (SGD-25) PH 7.4 Drugs which modify Ant. Pituitary Hormone		Micro Batch B (SGD) MI 7.3 - Lab diagnosis of UTI VI(IM)	
				Pharma - Batch A (SGD-26) PH1.11 ADRs Reporting-1	
				Path - Batch B (SGD) REVESION	
				FMT - Batch B (SGD) FM 2.17 Exhumation	

	<p>Micro (Lec) MI 7.2 Syphilis - 1 VI(DR/OG)</p>	<p>Patho (SDL) PA 28.11 Define classify and describe the etiology, pathogenesis pathology, laboratory, urinary findings, distinguishing features progression and complications of vascular disease of the kidney</p>		<p>Path - Batch A (SGD) REVISION</p> <p>FMT - Batch A (SGD) FM 2.17 Exhumation</p>
--	--	--	--	--

	Pharma (Lec-80) PH 7.5 Corticosteroids-1	Micro (LEC) MI 7.2 Syphilis - 2 VI(DR/OG)		2-3 PM Patho(SGD) PA 28.12 Define classify and describe the genetics, inheritance, etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features, progression and complications of cystic disease of the kidney	3-4 PM Pharma (SGD-27) PH 7.5 Corticosteroids-2
	Patho(Lec) PA 28.13 Define classify and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features progression and complications of renal stone disease and obstructive uropathy	Micro (Lec) MI 7.2 LGV & Chancroid VI(DR/OG)		Micro Batch A (SGD) MI 7.2 - Lab diagnosis of Syphilis VI(DR/OG)	
	Pharma (Tutorial-4) PH 7.6 Drugs used in erectile dysfunction & Androgens	Patho(SGD) PA 28.14 Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features, progression and spread of renal tumors		Pharma - Batch B (SGD-28) PH1.11 ADRs Reporting-2	
	Surgery (Lec.) SU 29.3 Urinary tract infections VI(MI)	Pharma (SDL-10) PH 7.7 Oral Contra- Ceptives VI(OG)		Micro Batch B (SGD) MI 7.2 - Lab diagnosis of Syphilis VI(DR/OG)	
				Pharma - Batch A (Practical) PH1.11 ADRs Reporting-3	
				Path - Batch B (SGD) REVISION	
				FMT - Batch B (SDL) FM 2.15 Medicolegal Autopsies	

	<p>Micro (Lec) MI 7.2 Bact Vaginosis & candidiasis VI(DR/OG)</p>	<p>Patho(Lec) PA 28.15 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies</p>		<p>Path - Batch A (SGD) REVISION</p>
				<p>FMT - Batch A (SDL) FM 2.15 Medicolegal Autopsies</p>
	<p>Pharma(Tutorial-5) PH7.8 Uterine Relaxants & Stimulants VI(OG)</p>	<p>Micro (Lec) MI 7.2 Viral STDs (Except HIV) VI(DR/OG)</p>		<p>2 – 3 PM Patho (SGD) PA 28.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of urothelial tumors</p>
				<p>3 – 4 PM (Tutorial-6) PH7.9 Drugs used in Infertility</p>
	<p>FMT. (Lec.) FM 2.13 Obscure Autopsy VI(PA)</p>	<p>Pharma Pharma(Tutoria-7) PH 9.4 Vaccine & sera</p>		<p>AETCOM (PH) Module 2.7: Bioethics continued – Case studies on patient autonomy and decision making (SDL)</p>
	<p>Patho (Lec.) PA 29.1 Classify testicular tumors and describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumors</p>	<p>Micro (Lec) MI 7.2 Parasitic STDs VI(DR/OG)</p>		<p>Micro Batch A (SGD) MI 7.2 - Lab diagnosis of Urethritis VI(DR/OG)</p>
	<p>Pharma (Tutorial-8) PH 9.2, Common Drugs poisoning</p>	<p>Patho(SGD) PA 29.2 Describe the pathogenesis, pathology, presenting and</p>		<p>Pharma - Batch B (Practical) PH1.11 ADRs Reporting-4</p>
				<p>Micro Batch A (SGD) MI 7.2 - Lab diagnosis of Urethritis VI(DR/OG)</p>

	& VI (IM)	distinguishing features, diagnostic tests, progression and spread of carcinoma of the penis		Pharma - Batch A (Practical) PH10.3 P drug Concept-1
	Medicine (Lec.) GM 10.1/2/3/4 Introduction to Renal Failure & ARF VI(PA)	Pharma (Tutorial-9) PH 9.3 Heavy metal poisoning VI (IM)		Path - Batch B (SGD) REVISION
	Micro (LEC) MI 4.3 Soft Tissue Infections - Staph. VI(SU/DR)	Patho (Lec) PA 29.3 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, urologic findings & diagnostic tests of benign prostatic hyperplasia		FMT. - Batch B (SGD) FM 2.20/21/22 Mechanical Asphyxia
	FMT.(Lec.) FM 2.23 Drowning	Pharma(Lec) PH 9.6 Drugs used in skin disorders VI(DE)-1		Path - Batch A (SGD) REVISION
				FMT. - Batch A (SGD) FM 2.20/21/22 Mechanical Asphyxia
				AETCOM (PH) Module 2.6: Bioethics continued – Case studies on patient autonomy and decision making Discussion & Case Closure

	<p>Patho(SGD) PA 29.4 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate</p>	<p>Micro (Lec) MI 4.3 Soft Tissue Infections - Strep. VI(SU/DR)</p>		<p>Micro Batch A (SGD) MI 4.3 Lab diagnosis of Staph. & Strepto. VI(SU/DR)</p>
	<p>Pharma (SGD-29) PH 9.6 Drugs used in skin disorders VI(DE)-2</p>	<p>Patho(Lec) PA 29.5 Describe the etiology, pathogenesis, pathology and progression of prostatitis</p>		<p>Micro Batch B (SGD) MI 4.3 Lab diagnosis of Staph. & Streptococcus VI(SU/DR)</p>
	<p>Surgery (Lec.) SU 29.1 Hematuria</p>	<p>Pharma (Tutorial-10) PH 9.5 Antiseptic & Disinfectant</p>		<p>Pharma - Batch B (Practical) PH10.3 P drug Concept-2</p>
	<p>Micro (LEC) MI 4.3 Soft Tissue Infections - Bacillus VI(SU/DR)</p>	<p>Patho (SGD) PA 30.1 Describe the epidemiology, pathogenesis, etiology, pathology, screening, diagnosis and progression of carcinoma of the cervix</p>		<p>Micro Batch B (SGD) MI 4.3 Lab diagnosis of Staph. & Streptococcus VI(SU/DR)</p>
				<p>Pharma - Batch A (Practical) PH10.3 P drug Concept-3</p>
				<p>Path - Batch B (SGD) REVISION</p>
				<p>FMT - Batch B (SGD) FM 2.23 PM findings of Drowning</p>
				<p>Path - Batch A (SGD) REVISION</p>
				<p>FMT - Batch A (SGD) FM 2.23 PM findings of Drowning</p>

	Pharma (Tutorial-11) PH9.1 Immunomodulators (Revision)	Micro (Lec) MI 4.3 Leprosy VI (DR)		Patho(SGD) PA 30.2 Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of carcinoma of the endometrium	3 - 4 PM Pharma (Seminar-10)
	FMT. (Lec.) FM 2.19 Inv. of Operative Deaths VI(AS/SU)	Pharma (Lec) Revision		PM-2.3 - Sample collection, lab diagnosis of Covid (MI)	
	Patho (Lec.) PA 30.3 Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of carcinoma of the leiomyomas and leiomyosarcomas	Micro (Lec) MI 4.3 Soft Tissue Infections - Actinomyces VI(SU/DR)		Micro Batch A (SGD) MI 4.3 Lab diagnosis of Leprosy VI(SU/DR)	
	Surgery (Lec.) SU 18.1 Subcutaneous Infections	Patho (Lec.) PA 30.4 Classify and describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of ovarian tumors		Pharma Batch B (Practical) PH10.3 P drug Concept-4	
				Micro Batch A (SGD) MI 4.3 Lab diagnosis of Leprosy VI(SU/DR)	
				Pharma Batch A (Practical) PH 10.8 Essential Medicine & fixed dose combination	

	<p>Med. (Lec.) GM 10.1/2 Describe & differentiate b/w Ac. & Chr. Renal failure VI(PA)</p>	<p>Pharma-11 Seminar</p>		<p>Path - Batch B (SGD) REVISION</p>
	<p>Micro (Lec) MI 4.1 Anaerobic Infections - Clostridium VI(IM)</p>	<p>Patho(Lec) PA 30.5 Describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of gestational trophoblastic neoplasms</p>		<p>FMT - Batch B (SGD) FM 2.26 PM findings in Starvation</p>
	<p>Pharma (Lec) Revision</p>	<p>Micro (Lec) MI 4.3 Skin Infections - Rickettsia VI(SU/DR)</p>		<p>Path - Batch A (SGD) REVISION</p>
	<p>FMT.(Lec.) FM 2.24 Thermal Deaths</p>	<p>Pharma (Seminar13)</p>		<p>FMT - Batch A (SGD) FM 2.26 PM findings in Starvation</p>
	<p>Patho (Lec.) 30.7</p>	<p>Micro (Lec) MI 4.3</p>		<p>2 – 3 PM Patho(SGD) PA 30.6 Describe the etiology and morphologic features of cervicitis</p>
				<p>3 – 4 PM Pharma Seminar-12</p>
				<p>MICROBIOLOGY MI 6.2 / 6.3 –URTI & LRTI – Grams Stain / Zn stain</p>
				<p>Micro Batch A (SGD) MI 4.3 - Lab diagnosis of papular skin diseases VI(DR)</p>

	Describe the etiology, hormonal dependence, features and morphology of endometriosis	Skin Viral Infections - 1 VI(DR)		Pharma Batch B (Practical) PH 10.8 Essential Medicine & fixed dose combination
	Medicine GM 10.3 Pre & post renal ARF VI (PA)	Patho (Lec.) PA 30.8 Describe the etiology and morphologic features of adenomyosis		Micro Batch B (SGD) MI 4.3 - Lab diagnosis of papular skin diseases VI(DR)
	Surgery (Lec.) SU 29.7 Acute & Chronic retention of urine	Pharma (Seminar-14)		Pharma Batch A (SGD-30) PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs
				Path - Batch B (SGD) REVESION
				FMT - Batch B (SGD) FM 2.25 PM findings in Burns VI(SU)

	Pharma (SGD) Revision	Micro (Lec) MI 4.3 Skin Viral Infections - 2 VI(DR)		2 – 3 PM Patho (SGD) PA 30.9 Describe the etiology, hormonal dependence and morphology of endometrial hyperplasia	3 – 4 PM Pharma (Seminar-15)
	FMT.(Lec.) FM 2.27 Infanticide, Foeticide, Still Birth VI(PE)	Pharma (Seminar-16)		MICROBIOLOGY MI 8.6 /8.7 hand Hygiene and PPE	
	Patho(Lec) PA 31.1 Classify and describe the types, etiology, pathogenesis, pathology and hormonal dependency of benign breast disease	Micro (Lec) MI 4.3 Skin Fungal Infections - Candida VI(DR)		Micro Batch A (SGD) MI 4.3 Lab Diagnosis Skin Fungal Infections VI (DR)	Pharma Batch B (SGD,Role Play-30) PH 10.13 Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs
	Surgery SU 18.1 Cutaneous infections	Patho (Lec.) PA 31.2 Classify and describe the epidemiology, pathogenesis, classification, morphology, prognostic factors, hormonal dependency, staging and spread of carcinoma of the breast		Micro Batch B (SGD) MI 4.3 Lab Diagnosis Skin Fungal Infections VI (DR)	Pharma Batch A (Role Play) PH 10.14 Communicate with pt. with empathy and ethics on all aspect of drug use

	Medicine (Lec.) GM 5.4 Alcoholic Liver Diseases	Pharma Seminar-17		Path - Batch A (SGD) REVISION
	Micro (Lec) MI 4.3 Skin Fungal Infections - Dermatophytes VI(DR)	Patho (Lec.) PA 31.4 Enumerate and describe the etiology, hormonal dependency and pathogenesis of gynecomastia		FM- Batch B (SGD) FM 2.25 PM findings in Burns VI(SU)
	FM.(Lec.) FM 2.28 IUD, Live Birth, Viability of Foetus VI(AN/PE)	Pharma Seminar-18		Path - Batch B (SGD) REVISION
	Patho (Lec.) PA 32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings	Micro (Lec) MI 4.3 Soft Tissue Fungal Infections - Mycetomas VI(DR)		FM- Batch A (SGD) FM 2.25 PM findings in Burns VI(SU)
	Medicine (Lec.) GM 17.1 Headache	Patho(Lec) PA 32.2 Describe the etiology, cause, iodine dependency, pathogenesis,		MICROBIOLOGY MI 8.6 /8.7 hand Hygiene and PPE
				Micro Batch A (SGD) MI 2.6 - Lab diagnosis of Mycetoma VI(DR)
				Pharma - Batch B (Role Play) PH 10.14 Communicate with pt. with empathy and ethics on all aspect of drug use
				Micro Batch B (SGD) MI 2.6 - Lab diagnosis of Mycetoma VI(DR)

	VI (AN)	manifestations, laboratory and imaging features and course of thyrotoxicosis		Pharma - Batch A (Role Play) PH10.14 Communicate with pt. regarding optimal use of: Drug therapy, Device, storage of medicine
	Surgery (Lec.) SU 30.6 Tumors of testis	Pharma Seminar-19		Path - Batch A (SGD) REVISION
	Micro (Lec) MI 5.1 Introduction & Pyogenic Meningitis HI(PA) VI(PE/IM)	Patho(Lec) PA 32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/ hypothyroidism		FM- Batch B (SGD) FM 2.9 Respect to Directions of Court
	Pharma (Lec.) Revision	Micro (Lec.) MI 5.1 Chronic Bacterial Meningitis HI(PA) VI(PE/IM)		Path - Batch B (SGD) REVISION
				2 -3 PM Patho (SGD) PA 32.4 Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features, complications and progression of diabetes mellitus
				3 – 4 PM Pharma Seminar-20

	<p>Medicine (Lec.) GM 17.7 CSF findings & Interpretation of Meningitis- 1 VI(MI, PA)</p>	<p>Pharma (Lec) Revision</p>		<p>MICROBIOLOGY (SGD) MI 8.8 / 8.9 Significance of assessing the microbial contamination / Appropriate method of collection of samples</p>
	<p>Patho (Lec.) PA 32.5 Describe the etiology, genetics, pathogenesis, manifestations, laboratory and morphologic features of hyperparathyroidism</p>	<p>Micro (Lec) MI 5.1 Fungal Meningitis HI(PA) VI(PE/IM)</p>		<p>Micro Batch A (SGD) MI 2.6 - Lab diagnosis of bacterial Meningitis VI(PE/IM)</p>
	<p>Surgery (Lec.) SU 29.9 Disorders of prostate</p>	<p>Patho (Lec.)PA 32.6 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications and metastases of pancreatic cancer</p>		<p>Pharma - Batch B (Role Play)) PH10.14 Communicate with pt. regarding optimal use of: Drug therapy, Device, storage of medicine</p>
	<p>Medicine (Lec.) GM 17.7 CSF findings & Interpretation of Meningitis-</p>	<p>Pharma (Lec) Revision</p>		<p>Micro Batch B (SGD) MI 2.6 - Lab diagnosis of bacterial Meningitis VI(PE/IM)</p>
	<p>Medicine (Lec.) GM 17.7 CSF findings & Interpretation of Meningitis-</p>	<p>Pharma (Lec) Revision</p>		<p>Pharma - Batch A (Role Play) PH 10.15 Motivate pts. Chronic diseases to adhere to prescribed management by health care provider</p>
				<p>Path - Batch A (SGD) REVISION</p>

	2 VI(MI, PA)			FM - Batch B (SGD) FM 8.3/4 Poisons, Toxicokinetics&Toxicodynamics
	Micro (Lec) MI 5.1 Parasitic Meningoencephalitis HI(PA) VI(PE/IM)	Patho (Lec)PA 32.7 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications of adrenal insufficiency		Path - Batch B (SGD) REVISION
	Pharma (Lec) Revision	Micro (Lec) MI 5.1 Viral Meningitis - JE HI(PA) VI(PE/IM)		FM- Batch A (SGD) FM 8.3/4 Poisons, Toxicokinetics&Toxicodynamics
			2 – 3 pmPatho(Lec) PA 32.8 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications of Cushing's syndrome	3 - 4 PM Pharma Seminar-21

	Surgery (Lec.) SU 1.1 Metabolic response to injury VI (PY,BI)	Pharma(Lec) Revision		MICROBIOLOGY (SGD) MI 8.10/8.11 Appropriate method of collection of samples / Respect for patient samples sent
--	--	-------------------------	--	--

	<p>Patho (Lec) PA 32.9 Describe the etiology, pathogenesis, manifestations, laboratory and morphologic features of adrenal neoplasms</p>	<p>Micro (Lec) MI 5.2 Viral Encephalitis - Echovirus HI(PA) VI(PE/IM)</p>	<p>Micro Batch A (SGD) MI 2.6 - Lab diagnosis of viral Meningoencephalitis VI(PE/IM)</p>
			<p>Pharma - Batch B (Role Play) PH 10.15 Motivate pts. Chronic diseases to adhere to prescribed management by health care provider</p>
	<p>Medicine (Lec.) GM 22.2 Poisoning VI(PH,FM)</p>	<p>Patho. (Lec) PA 33.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis</p>	<p>Micro Batch B (SGD) MI 2.6 - Lab diagnosis of viral Meningoencephalitis VI(PE/IM)</p>
			<p>Pharma - Batch A (SGD) PH 10.16 & 10.17</p>
	<p>SURGERY (Lec.) SU 1.2 Factors affecting metabolic response to injury VI (BI)</p>	<p>Pharma (Lec) Revision</p>	<p>Path - Batch A (SGD) REVESION</p>
			<p>Micro (SDL) Batch A MI 2.6 Meningitis & Meningoencephalitis</p>
	<p>Micro (Lec) MI 5.2 Viral Encephalitis - Rabies HI(PA) VI(PE/IM)</p>	<p>Patho (Lec.) PA 33.2 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumors</p>	<p>Path - Batch B (SGD) REVESION</p>
			<p>Micro (SDL) Batch B Mi 2.6 Meningitis & Meningoencephalitis</p>

	Pharma (SDL) Revision	Micro (Lec) MI 5.2 Viral Encephalitis - Polio HI(PA) VI(PE/IM)	2-3PM,Patho(SGD) PA 33.3Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of soft.. tissue tumors	3 – 4 PM Pharma (Seminar- 21)
	Medicine (Lec.) GM 26.31 Common Zoonotic diseases- 1 VI(MI, CM)	Pharma (SDL) Revision	Path - Batch A (SGD) REVESION	
	Patho (Lec) PA 33.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of Paget's disease of the bone	Micro (Lec) MI 8.1 Bacterial Zoonotic Diseases VI(IM)	MICRO AETCOM 8.14- Batch A Demonstrate Confidentiality to patient identity in laboratory results	
	Surgery(Lec) SU 1.3 Basics concepts of perioperative care	Patho (Lec.) PA 33.5 Classify and describe the etiology, immunology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of rheumatoid arthritis	Patho(SGD)- Batch B PA 33.5 REVESION	
	Medicine (Lec.) GM 26.32 Common Zoonotic diseases- 2 VI(MI, CM)	Pharma (Lec) Revision	MICRO AETCOM 8.14- Batch B Demonstrate Confidentiality to patient identity in laboratory results	
			Patho(SGD)- Batch A REVESION	
			Patho (SGD)- Batch B REVESION	

			Batch B (SGD) Pharma PH 10.16 & 10.17
	Micro (Lec) MI 8.1 Parasitic Zoonotic Diseases-1 VI(IM)	Patho (SGD) PA 34.1 Describe the risk factors pathogenesis, pathology and natural history of squamous cell carcinoma of the skin	Patho (SGD)- Batch A REVISION
	Patho (Lec) PA 34.2 Describe the risk factors pathogenesis, pathology and natural history of basal cell carcinoma of the skin	Micro (SDL) MI 8.1 Parasitic Zoonotic Diseases - 2 VI(IM)	Batch A (SGD) Pharma Revision
			Patho (SGD) 2 - 3 PM PA 34.3 Describe the distinguishing features between a nevus and melanoma. Describe the etiology, pathogenesis, risk factors morphology clinical features and metastases of melanoma
			PATHO (L) PA- 36.1 Describe the etiology, genetics, pathogenesis, pathology, presentation, sequelae and complications of retinoblastoma
	Surgery SU 22.2 Thyroidal swellings VI (PA) VI(PY/PA)	Patho (SGD) PA 35.1 Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis	MICROBIOLOGY (SGD) MI 8.13 / 8.15 / 8.16 Appropriate laboratory test in the diagnosis of the infectious disease / Interpret the results of the laboratory tests used in diagnosis of the infectious disease / National Health Programs in the prevention of common infectious disease

Patho (Lec)
PA 35.2
Classify and describe the
etiology, genetics,
pathogenesis, pathology,
presentation sequelae and
complications of CNS
tumors

Micro (Lec)
MI 8.3
Viral Oncogenesis
HI(PA) VI(IM)

**MICRO AETCOM 8.14
Assessment**

PREPERATORY LEAVE FOR UNIVERSITY EXAMINATIONS

ASSESSMENT SCHEDULE

FIRST INTERNAL ASSESSMENT EXAMINATION	4 MONTHS AFTER START OF SESSION
SECOND INTERNAL ASSESSMENT EXAMINATION	7 MONTHS AFTER START OF SESSION
PRE-UNIVERSITY EXAMINATION	1 MONTH BEFORE
PHASE 3 PART 2 SUBJECT EXAMINATION	15 DAYS BEFORE UNIVERSITY EXAMINATION
UNIVERSITY EXAMINATION	AS PER NMC/ ATAL UNIVERSITY SCHEDULE

CALCULATION OF TOTAL NUMBR OF HOURS
FOR ALL SEGMENTS OF EACH SUBJECT IN GIVEN TIME TABLE

SUBJECT	LECTURES	SMALL GROUP TEACHING / TUTORIAL / INTEGRATED LEARNING / PRTACTICALS	Clinical Postings (hours*)	SDL	TOTAL (IN HOURS)
PATHOLOGY	82	170	0	12	264
PHARMACOLOGY	88	170	0	12	270
MICROBIOLOGY	80	140	0	10	230
COMMUNITY MEDICINE	15	--	0	10	25
FAMILY ADOPTION PROGRAMME	--	--	30	--	30
FORENSIC MEDICINE & TOXICOLOGY	15	30	0	8	53
CLINICAL SUBJECTS	75		627	--	702
	(MI=25/SU=25/O G=25)				
AETCOM MODULE	--	29	0	8	37
PANDEMIC MODULE	--	--	0	28	28
SPORTS & EXTRACURRICULAR ACTIVITIES	--	--	--	35	35
TOTAL	355	539	657	123	1674

CALCULATION OF TOTAL NUMBR OF HOURS
FOR ALL SEGMENTS OF EACH SUBJECT IN THE TIME TABLE

SUBJECT	LECTURES	SMALL GROUP TEACHING / TUTORIAL / INTEGRATED LEARNING / PRTACTICALS	Clinical Postings (hours*)	SDL	TOTAL (IN HOURS)
PATHOLOGY	82	170	0	12	264
PHARMACOLOGY	88	170	0	12	270
MICROBIOLOGY	80	140	0	10	230
COMMUNITY MEDICINE	15	--	0	10	25
FAMILY ADOPTION PROGRAMME	--	--	30	--	30
FORENSIC MEDICINE & TOXICOLOGY	15	30	0	8	53
CLINICAL SUBJECTS	75 (MI=25/SU=25/O G=25)		627	--	702
AETCOM MODULE	--	29	0	8	37
PANDEMIC MODULE	--	--	0	28	28
SPORTS & EXTRACURRICULAR ACTIVITIES	--	--	--	35	35
TOTAL	355	539	657	123	1674

Dr. Sunil Sharma
 In Charge, Student cell
 Dr KNS MIMS

In Charge
Student Cell
Dr. KNS MIMS

Dr. N.K. Mohindroo
 Dean
 Dr KNS MIMS

CC: - 1. Hon'ble Chairperson, 2. Hon'ble Vice Chairman, 3. Hon'ble Pro-Vice Chancellor, 4. Dean Office, 5. Dean Academics, 6. Registrar, 7. Concerned Departments, 8. Notice Board

